Symptom scales | ||||||
---|---|---|---|---|---|---|
Painful sites | Intervention group (Arm A) | Control group (Arm B) | ||||
n | Mean | SD | n | Mean | SD | |
Baseline (t0) | 30 | 39.78 | 23.91 | 30 | 39.56 | 24.51 |
3 month (t2) | 25 | 29.6 | 19.73 | 22 | 35.76 | 27.1 |
6 month (t3) | 18 | 22.22 | 13.14 | 18 | 35.93 | 32.67 |
Treatment effect (t0-t2) after 3 month p = 0.399, (t0-t3) after 6 month p = 0.445 | ||||||
Effect size (t0-t2) after 3 month -0.24, (t0-t3) after 6 month -0.43 | ||||||
Pain characteristics | Intervention group (Arm A) | Control group (Arm B) | ||||
n | Mean | SD | n | Mean | SD | |
Baseline (t0) | 30 | 48.15 | 31.47 | 30 | 54.81 | 33.13 |
3 month (t2) | 25 | 25.78 | 17.78 | 22 | 41.92 | 35.62 |
6 month (t3) | 18 | 25.31 | 19.73 | 18 | 45.06 | 36.65 |
Treatment effect (t0-t2) after 3 month p = 0.905, (t0-t3) after 6 month p = 0.761 | ||||||
Effect size (t0-t2) after 3 month -0.09, (t0-t3) after 6 month -0.24 | ||||||
Functional interference | Intervention group (Arm A) | Control group (Arm B) | ||||
n | Mean | SD | n | Mean | SD | |
Baseline (t0) | 30 | 55.14 | 26.32 | 30 | 55.28 | 28.95 |
3 month (t2) | 25 | 35.33 | 20.35 | 22 | 44.7 | 30.38 |
6 month (t3) | 18 | 29.86 | 20.77 | 18 | 48.38 | 30.12 |
Treatment effect (t0-t2) after 3 month p = 0.285, (t0-t3) after 6 month p = 0.081 | ||||||
Effect size (t0-t2) after 3 month -0.21, (t0-t3) after 6 month -0.56 | ||||||
Psychosocial aspects | Intervention group (Arm A) | Control group (Arm B) | ||||
n | Mean | SD | n | Mean | SD | |
Baseline (t0) | 30 | 69.26 | 17.0 | 30 | 57.59 | 19.87 |
3 month (t2) | 25 | 45.56 | 19.71 | 23 | 54.55 | 20.9 |
6 month (t3) | 18 | 41.05 | 19.1 | 18 | 50.93 | 20.55 |
Treatment effect (t0-t2) after 3 month p = 0.001, (t0-t3) after 6 month p = 0.010 | ||||||
Effect size (t0-t2) after 3 month -0.79, (t0-t3) after 6 month -0.77 |